The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Open accessAbstract
OBJECTIVE: To evaluate clinical features among patients with neuromyelitis optica spectrum disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies. METHODS: Sera from patients diagnosed with NMOSD in 1 of 3 centers (2 sites in Brazil and 1 site in Japan) were tested for MOG and AQP4 antibodies using cell-based assays with live transfected cells. RESULTS: Among the 215 patients with NMOSD, 7.4% (16/215) were positive for MOG antibodies and 64.7% (139/215) were positive for AQP4 antibodies. No patients were positive for both antibodies. Patients with MOG antibodies represented 21.1% (16/76) of the patients negative for AQP4 antibodies. Compared with patients with AQP4 antibodies or patients who were seronegative, patients with MOG antibodies were more frequently male, had a more restricted phenotype (optic nerve more than spinal cord), more frequently had bilateral simultaneous optic neuritis, more often had a single attack, had spinal cord lesions distributed in the lower portion of the spinal cord, and usually demonstrated better functional recovery after an attack. CONCLUSIONS: Patients with NMOSD with MOG antibodies have distinct clinical features, fewer attacks, and better recovery than patients with AQP4 antibodies or patients seronegative for both antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Panel members agreed that the 2010 McDonald Criteria and 2015 International Panel for NMO Diagnosis Criteria 52 largely distinguish MS and NMOSD, though uncertain cases can occur, particularly with AQP4-seronegative patients.”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. E., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,819
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre
Takahashi, T., Fujihara, K., Nakashima, I., Misu, T., Miyazawa, I., Nakamura, M., Watanabe, S., Shiga, Y., Kanaoka, C., Fujimori, J., et al. (2007) · Brain · doi:10.1093/brain/awm062 · Cited by 633
Kitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597
Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays
Waters, P. J., McKeon, A., Leite, M. I., Rajasekharan, S., Lennon, V. A., Villalobos, A., Palace, J., Mandrekar, J. N., Vincent, A., Bar-Or, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318248dec1 · Cited by 526
Self-citationMader, S., Gredler, V., Schanda, K., Rostasy, K. M., Dujmović, I., Pfaller, K., Lutterotti, A., Jarius, S., Pauli, F. D., Kuenz, B., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-184 · Cited by 449
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype
Kitley, J., Woodhall, M., Waters, P., Leite, M. I., Devenney, E., Craig, J., Palace, J., & Vincent, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31826aac4e · Cited by 445
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
O’Connor, K. C., McLaughlin, K. A., Jager, P. L. D., Chitnis, T., Bettelli, E., Xu, C., Robinson, W. H., Cherry, S. V., Bar‐Or, A., Banwell, B., et al. (2007) · Nature Medicine · doi:10.1038/nm1488 · Cited by 419
The spectrum of MOG autoantibody-associated demyelinating diseases
Reindl, M., Pauli, F. D., Rostasy, K. M., & Berger, T. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.118 · Cited by 376
Cited by
Sorted by citations
Items 101–200 of 848
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
Kleiter, I., & Gold, R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0400-8 · Cited by 109
Differential diagnosis of neuromyelitis optica spectrum disorders
Kim, S., Kim, S.-J., Lee, H. J., Kuroda, H., Palace, J. A., & Fujihara, K. (2017) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617709723 · Cited by 114
Body fluid biomarkers for multiple sclerosis—the long road to clinical application
Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.173 · Cited by 106
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies
Kaneko, K., Sato, D. K., Nakashima, I., Nishiyama, S., Tanaka, S., Marignier, R., Hyun, J.-W., Oliveira, L. M. D., Reindl, M., Seifert-Held, T., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312676 · Cited by 106
Neuromyelitis optica spectrum disorders in children and adolescents
Tenembaum, S., Chitnis, T., Nakashima, I., Collongues, N., McKeon, A. B., Levy, M., & Rostasy, K. M. (2016) · Neurology · doi:10.1212/wnl.0000000000002824 · Cited by 110
Filippatou, A. G., Mukharesh, L., Saidha, S., Calabresi, P. A., & Sotirchos, E. S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.540156 · Cited by 109
Overlapping CNS inflammatory diseases: differentiating features of NMO and MS
Juryńczyk, M., Craner, M. J., & Palace, J. A. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308984 · Cited by 106
Advances in spinal cord imaging in multiple sclerosis
Moccia, M., Ruggieri, S., Ianniello, A., Toosy, A., Pozzilli, C., & Ciccarelli, O. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419840593 · Cited by 106
Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
the Australasian and New Zealand MOG Study Group, Tea, F., Lopez, J. A., Ramanathan, S., Merheb, V., Lee, F. X. Z., Zou, A., Pilli, D., Patrick, E., van der Walt, A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0786-3 · Cited by 108
Kothur, K., Wienholt, L. A., Tantsis, E. M., Earl, J. W., Bandodkar, S., Prelog, K., Tea, F., Ramanathan, S., Brilot, F., & Dale, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149411 · Cited by 106
MRI features of demyelinating disease associated with anti-MOG antibodies in adults
Denève, M., Biotti, D., Patsoura, S., Ferrier, M., Meluchova, Z., Mahieu, L., Héran, F., Vignal‐Clermont, C., Deschamps, R., Gout, O., et al. (2019) · Journal of Neuroradiology · doi:10.1016/j.neurad.2019.06.001 · Cited by 101
Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?
Reindl, M., Jarius, S., Rostasy, K. M., & Berger, T. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000446 · Cited by 100
Zhao, Y., Tan, S., Chan, T. C. Y., Xu, Q., Zhao, J., Teng, D., Fu, H., & Wei, S. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311177 · Cited by 100
MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders
Shahriari, M., Sotirchos, E. S., Newsome, S. D., & Yousem, D. M. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.20.24061 · Cited by 105
Updates in NMOSD and MOGAD Diagnosis and Treatment
Cacciaguerra, L., & Flanagan, E. P. (2023) · Neurologic Clinics · doi:10.1016/j.ncl.2023.06.009 · Cited by 112
Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders
Takai, Y., Misu, T., Suzuki, H., Takahashi, T., Okada, H., Tanaka, S., Okita, K., Sasou, S., Watanabe, M., Namatame, C., et al. (2021) · Brain · doi:10.1093/brain/awab102 · Cited by 102
Brain and cord imaging features in neuromyelitis optica spectrum disorders
Cacciaguerra, L., Meani, A., Mesaroš, Š., Radaelli, M., Palace, J. A., Dujmović, I., Pagani, E., Martinelli, V., Matthews, L., Drulovic, J. S., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25411 · Cited by 99
Sotirchos, E. S., Filippatou, A., Fitzgerald, K. C., Salama, S., Pardo, S., Wang, J., Ogbuokiri, E., Cowley, N. J., Pellegrini, N., Murphy, O. C., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519864928 · Cited by 98
Zhou, L., Huang, Y., Li, H., Fan, J., ZhangBao, J., Yu, H., Li, Y., Lu, J., Zhao, C., Lü, C., et al. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.01.007 · Cited by 96
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations
Juryńczyk, M., Jacob, A., Fujihara, K., & Palace, J. A. (2018) · Practical Neurology · doi:10.1136/practneurol-2017-001787 · Cited by 95
Mariano, R., Messina, S., Kumar, K. A., Küker, W., Leite, M. I., & Palace, J. A. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12732 · Cited by 95
Predictors of relapse in MOG antibody associated disease: a cohort study
Huda, S., Whittam, D. H., Jackson, R., Karthikeayan, V., Kelly, P., Linaker, S., Mutch, K., Kneen, R., Woodhall, M. R., Murray, K., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-055392 · Cited by 94
Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan
Houzen, H., Kondo, K., Niino, M., Horiuchi, K., Takahashi, T., Nakashima, I., & Tanaka, K. (2017) · Neurology · doi:10.1212/wnl.0000000000004611 · Cited by 93
Elsbernd, P. M., Hoffman, W. R., Carter, J. L., & Wingerchuk, D. M. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102696 · Cited by 93
Oertel, F. C., Zimmermann, H. G., Paul, F., & Brandt, A. U. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0123-5 · Cited by 95
A population-based prospective study of optic neuritis
Soelberg, K. K., Jarius, S., Skejoe, H., Engberg, H., Mehlsen, J., Nilsson, A. C., Madsen, J. S., Reindl, M., Wildemann, B., Grauslund, J., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517734070 · Cited by 90
Cobo‐Calvo, Á., Sepúlveda, M., Bernard‐Valnet, R., Ruiz, A., Brassat, D., Martínez‐Yélamos, S., Saiz, A., & Marignier, R. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515591071 · Cited by 88
Havla, J. B., Kümpfel, T., Schinner, R., Spadaro, M., Schuh, E., Meinl, E., Hohlfeld, R., & Outteryck, O. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8333-7 · Cited by 88
Akaishi, T., Takahashi, T., Misu, T., Kaneko, K., Takai, Y., Nishiyama, S., Ogawa, R., Fujimori, J., Ishii, T., Aoki, M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012175 · Cited by 88
Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder
Hyun, J., Jeong, I. H., Joung, A., Kim, S., & Kim, H. J. (2016) · Neurology · doi:10.1212/wnl.0000000000002655 · Cited by 86
Jarius, S., Lechner, C., Wendel, E. M., Baumann, M., Breu, M., Schimmel, M., Karenfort, M., Marina, A. D., Merkenschlager, A., Thiels, C., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01825-1 · Cited by 89
Contentti, E. C., Rojas, J. I., Cristiano, E., Marques, V. D., Flores-Rivera, J. D. J., Lana–Peixoto, M. A., Navas, C., Alvarenga, R. M. P., Sato, D. K., de Castillo, I. S., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102428 · Cited by 89
Seok, J. M., Cho, H.-J., Ahn, S.-W., Cho, E. B., Park, M. S., Joo, I.-S., Shin, H. Y., Kim, S., Kim, B., Kim, J. K., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458516685416 · Cited by 83
MOG antibody-associated optic neuritis
Jeyakumar, N., Lerch, M., Dale, R. C., & Ramanathan, S. (2024) · Eye · doi:10.1038/s41433-024-03108-y · Cited by 80
Flórez‐Grau, G., Zubizarreta, I., Cabezón, R., Villoslada, P., & Benítez‐Ribas, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01169 · Cited by 80
Lopez, J. A., Denkova, M., Ramanathan, S., Dale, R. C., & Brilot, F. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1316 · Cited by 79
Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis
Nakajima, H., Motomura, M., Tanaka, K., Fujikawa, A., Nakata, R., Maeda, Y., Shima, T., Mukaino, A., Yoshimura, S., Miyazaki, T., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007766 · Cited by 78
Shen, T., You, Y., Arunachalam, S., Fontes, A., Liu, S., Gupta, V., Parratt, J. D. E., Wang, C., Barnett, M. H., Barton, J., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.06.022 · Cited by 78
Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity
Chien, C., Scheel, M., Schmitz‐Hübsch, T., Borisow, N., Ruprecht, K., Bellmann–Strobl, J., Paul, F., & Brandt, A. U. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518815596 · Cited by 78
MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice
Hennes, E.-M., Baumann, M., Lechner, C., & Rostasy, K. M. (2017) · Neuropediatrics · doi:10.1055/s-0037-1604404 · Cited by 76
Gastaldi, M., Foiadelli, T., Greco, G., Scaranzin, S., Rigoni, E., Masciocchi, S., Ferrari, S., Mancinelli, C. R., Brambilla, L., Mancardi, M. M., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330237 · Cited by 76
de Oliveira, L. M., Apóstolos‐Pereira, S. L., Pitombeira, M. S., Torretta, P. H. B., Callegaro, D., & Sato, D. K. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518811597 · Cited by 75
MOG antibody-associated diseases
Reindl, M., & Rostasy, K. M. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000060 · Cited by 75
Cranial nerve involvement in patients with MOG antibody–associated disease
Cobo‐Calvo, Á., Ayrignac, X., Kerschen, P., Horellou, P., Cotton, F., Labauge, P. M., Vukusic, S., Deiva, K., Serguera, C., & Marignier, R. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000543 · Cited by 74
Trewin, B. P., Brilot, F., Reddel, S., Dale, R. C., & Ramanathan, S. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103693 · Cited by 82
Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest
Eshaghi, A., Wottschel, V., Cortese, R., Calabrese, M., Sahraian, M. A., Thompson, A. J., Alexander, D. C., & Ciccarelli, O. (2016) · Neurology · doi:10.1212/wnl.0000000000003395 · Cited by 74
The Gut Microbiome in Neuromyelitis Optica
Zamvil, S. S., Spencer, C. M., Baranzini, S. E., & Cree, B. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0594-z · Cited by 73
Longitudinally extensive transverse myelitis
Tobin, W. O., Weinshenker, B. G., & Lucchinetti, C. F. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000093 · Cited by 73
Different etiologies and prognoses of optic neuritis in demyelinating diseases
Akaishi, T., Nakashima, I., Takeshita, T., Kaneko, K., Mugikura, S., Sato, D. K., Takahashi, T., Nakazawa, T., Aoki, M., & Fujihara, K. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.09.007 · Cited by 72
Treatment and outcome of aquaporin-4 antibody–positive NMOSD
Paolilo, R. B., Hacohen, Y., Yazbeck, E., Armangué, T., Bruijstens, A. L., Lechner, C., Apóstolos‐Pereira, S. L., Martynenko, Y., Breu, M., Rimkus, C. D. M., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000837 · Cited by 72
Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids
Matsumoto, Y., Kaneko, K., Takahashi, T., Takai, Y., Namatame, C., Kuroda, H., Misu, T., Fujihara, K., & Aoki, M. (2023) · Brain · doi:10.1093/brain/awad122 · Cited by 72
Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder
Sherman, E., & Han, M. H. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0378-x · Cited by 72
Neuromyelitis Optica Spectrum Disorders
Flanagan, E. P., & Weinshenker, B. G. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0483-3 · Cited by 73
Ikeda, K., Kiyota, N., Kuroda, H., Sato, D. K., Nishiyama, S., Takahashi, T., Misu, T., Nakashima, I., Fujihara, K., & Aoki, M. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514551455 · Cited by 71
Nakamura, Y., Nakajima, H., Tani, H., Hosokawa, T., Ishida, S., Kimura, F., Kaneko, K., Takahashi, T., & Nakashima, I. (2017) · BMC Neurology · doi:10.1186/s12883-017-0858-6 · Cited by 71
Ramanathan, S., O’Grady, G. L., Malone, S., Spooner, C. G., Brown, D. A., Gill, D. S., Brilot, F., & Dale, R. C. (2018) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14032 · Cited by 71
Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update
Sasso, B. L., Agnello, L., Bivona, G., Bellia, C., & Ciaccio, M. (2019) · Medicina · doi:10.3390/medicina55060245 · Cited by 75
Oertel, F. C., Schließeit, J., Brandt, A. U., & Paul, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00608 · Cited by 71
HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population
Bruijstens, A. L., Wong, Y. Y. M., van Pelt, D., van der Linden, P. J. E., Haasnoot, G. W., Hintzen, R. Q., Claas, F. H. J., Neuteboom, R. F., & Wokke, B. H. A. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000702 · Cited by 70
Ciron, J., Cobo‐Calvo, Á., Audoin, B., Bourre, B., Brassat, D., Cohen, M., Collongues, N., Deschamps, R., Durand‐Dubief, F., Laplaud, D. A., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519849511 · Cited by 70
Oertel, F. C., Outteryck, O., Knier, B., Zimmermann, H. G., Borisow, N., Bellmann–Strobl, J., Blaschek, A., Jarius, S., Reindl, M., Ruprecht, K., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1521-5 · Cited by 68
Clinical and neuroimaging findings in MOGAD–MRI and OCT
Bartels, F., Lu, A., Oertel, F. C., Finke, C., Paul, F., & Chien, C. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13641 · Cited by 68
MOG CNS Autoimmunity and MOGAD
Moseley, C. E., Virupakshaiah, A., Forsthuber, T. G., Steinman, L., Waubant, E. L., & Zamvil, S. S. (2024) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200275 · Cited by 68
Stiebel‐Kalish, H., Lotan, I., Brody, J., Chodick, G., Bialer, O., Marignier, R., Bach, M., & Hellmann, M. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170847 · Cited by 69
Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults
The OFSEP Group, Cobo‐Calvo, Á., The REEM Group, Sepúlveda, M., d’Indy, H., Armangué, T., Ruiz, A., Maillart, É., Papeix, C., Audoin, B., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-018-9160-9 · Cited by 67
Li, S., Ren, H., Xu, Y., Xu, T., Zhang, Y., Yin, H., Zhang, W., Li, J., Ren, X., Fang, F., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000705 · Cited by 66
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
Juryńczyk, M., Weinshenker, B. G., Akman‐Demir, G., Asgari, N., Barnes, D., Boggild, M., Chaudhuri, A., D'hooghe, M. B., Evangelou, N., Geraldes, R., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7952-8 · Cited by 66
Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study
Demuth, S., Guillaume, M., Bourre, B., Ciron, J., Zéphir, H., Sirejacob, Y., Kerbrat, A., Lebrun‐Frénay, C., Papeix, C., Michel, L., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02420-2 · Cited by 65
Kleerekooper, I., Houston, S., Dubis, A. M., Trip, S. A., & Petzold, A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.604049 · Cited by 64
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD
Yan, Y., Li, Y., Fu, Y., Yang, L., Su, L., Shi, K., Li, M., Liu, Q., Borazanci, A., Liu, Y., et al. (2016) · Science China Life Sciences · doi:10.1007/s11427-015-4997-y · Cited by 63
Recent developments in MOG-IgG associated neurological disorders
Hegen, H., & Reindl, M. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420945135 · Cited by 68
Longitudinal Retinal Changes in MOGAD
Oertel, F. C., Sotirchos, E. S., Zimmermann, H. G., Motamedi, S., Specovius, S., Asseyer, S., Chien, C., Cook, L. J., Vasileiou, E. S., Filippatou, A. G., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26440 · Cited by 65
Ruiz‐Gaviria, R., Baracaldo, I., Castañeda, C., Ruíz-Patiño, A., Acosta-Hernández, A. L., & Rosselli, D. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.06.003 · Cited by 63
Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders
Hinson, S. R., Lennon, V. A., & Pittock, S. J. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63432-0.00021-9 · Cited by 65
Wong, Y. Y. M., Hacohen, Y., Armangué, T., Wassmer, E., Verhelst, H., Hemingway, C. A., van Pelt, E. D., Catsman‐Berrevoets, C. E., Hintzen, R. Q., Deiva, K., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13602 · Cited by 62
Pauli, F. D., & Berger, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02753 · Cited by 62
Duan, Y., Zhuo, Z., Li, H., Tian, D., Li, Y., Yang, L., Gao, C., Zhang, T., Zhang, X., Shi, F., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-324826 · Cited by 64
Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
Wang, Z., & Yan, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01785 · Cited by 63
MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity
Yandamuri, S. S., Filipek, B., Obaid, A., Lele, N., Thurman, J. M., Makhani, N., Nowak, R. J., Guo, Y. X., Lucchinetti, C. F., Flanagan, E. P., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165373 · Cited by 60
Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review
Pereira, W. L. D. C. J., Reiche, E. M. V., Kallaur, A. P., & Kaimen-Maciel, D. R. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.05.034 · Cited by 64
Spinal-generated movement disorders: a clinical review
Termsarasab, P., Thammongkolchai, T., & Frucht, S. J. (2015) · Journal of Clinical Movement Disorders · doi:10.1186/s40734-015-0028-1 · Cited by 60
Clinical Characteristics and Treatment of MOG-IgG–Associated Optic Neuritis
Tajfirouz, D. A., Bhatti, M. T., & Chen, J. J.-W. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-1014-z · Cited by 60
Mechanisms for lesion localization in neuromyelitis optica spectrum disorders
Bradl, M., Reindl, M., & Lassmann, H. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000551 · Cited by 60
The changing landscape of optic neuritis: a narrative review
Lott, L. B. D., Bennett, J. L., & Costello, F. (2021) · Journal of Neurology · doi:10.1007/s00415-020-10352-1 · Cited by 61
Gospe, S. M., Chen, J. J.-W., & Bhatti, M. T. (2020) · Eye · doi:10.1038/s41433-020-01334-8 · Cited by 60
MRI Characteristics of NMO, MOG and MS Related Optic Neuritis
Winter, A. W., & Chwalisz, B. K. (2020) · Seminars in Ophthalmology · doi:10.1080/08820538.2020.1866027 · Cited by 58
CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease
Rosenthal, J. F., Hoffman, B. M., & Tyor, W. R. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001126 · Cited by 58
Double-negative neuromyelitis optica spectrum disorder
Wu, Y. T., Geraldes, R., Juryńczyk, M., & Palace, J. A. (2023) · Multiple Sclerosis Journal · doi:10.1177/13524585231199819 · Cited by 57
Chen, L., Chen, C., Zhong, X., Sun, X., Zhu, H., Li, X., Yang, H., Shu, Y., Chang, Y., Hu, X., et al. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.05.014 · Cited by 58
2017 McDonald diagnostic criteria: A review of the evidence
McNicholas, N., Hutchinson, M., McGuigan, C., & Chataway, J. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.05.011 · Cited by 65
What You Need to Know About AQP4, MOG, and NMOSD
Prasad, S., & Chen, J. L. (2019) · Seminars in Neurology · doi:10.1055/s-0039-3399505 · Cited by 58
The long‐term outcome of MOGAD: An observational national cohort study of 61 patients
Deschamps, R., Pique, J., Ayrignac, X., Collongues, N., Audoin, B., Zéphir, H., Ciron, J., Cohen, M., Aboab, J., Mathey, G., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14746 · Cited by 55
Reactive Astrocytes and Emerging Roles in Central Nervous System (CNS) Disorders
Liddelow, S. A., Olsen, M. L., & Sofroniew, M. V. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041356 · Cited by 55
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Juryńczyk, M., Probert, F., Yeo, T., Tackley, G., Claridge, T. D. W., Cavey, A., Woodhall, M. R., Arora, S., Winkler, T., Schiffer, E., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0495-8 · Cited by 57
Zhou, J., Lu, X., Zhang, Y., Ji, T., Jin, Y., Xu, M., Bao, X., Zhang, Y., Xiong, H., Chang, X., et al. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.12.001 · Cited by 54
Demyelinating diseases in Asia
Ochi, H., & Fujihara, K. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000328 · Cited by 54
Takeshige‐Amano, H., Miyamoto, N., Shimura, H., Sato, D. K., Fujihara, K., Ueno, S., Nakamura, R., Ueno, Y., Watanabe, M., Hattori, N., et al. (2014) · BMC Neurology · doi:10.1186/s12883-014-0224-x · Cited by 53
Acute disseminated encephalomyelitis: current knowledge and open questions
Steiner, I., & Kennedy, P. G. E. (2015) · Journal of NeuroVirology · doi:10.1007/s13365-015-0353-z · Cited by 53
Inflammatory demyelination without astrocyte loss in MOG antibody–positive NMOSD
Wang, J. J., Jaunmuktane, Z., Mummery, C. J., Brandner, S., Leary, S. M., & Trip, S. A. (2016) · Neurology · doi:10.1212/wnl.0000000000002844 · Cited by 51
Metadata
- Authors
- Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., Lino, A. M. M., Misu, T., Leite, M. I., Aoki, M., & Fujihara, K.
- Affiliations
- Universidade Federal de Minas Gerais (BR)
- From the Departments of Neurology (D.K.S., T.T., I.N., M.A.) and Multiple Sclerosis Therapeutics (T.M., K.F.), Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Neurology (D.C., F.M.d.H.J., S.L.A.-P., R.F.S., A.M.M.L.), Faculty of Medicine, University of São Paulo, Brazil; CIEM MS Research Center (M.A.L.-P., N.T.), Federal University of Minas Gerais Medical School, Belo Horizonte, Brazil; Neuroimmunology Group (P.J.W., M.I.L.), Nuffield Department of Clinical Neurosciences,...
- ORCID
- Venue
- Neurology
- Published
- 2014-02-11
- Volume
- 82
- Issue
- 6
- Pages
- 474-481
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC3937859
- OpenAlex
- W2103812851
- Cited by
- 850
- References
- 21
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 45 · 2023: 67 · 2022: 69 · 2021: 94 · 2020: 95 · 2019: 83 · 2018: 76 · 2017: 82 · 2016: 66 · 2015: 66 · 2014: 38
- FWCI
- 62.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (22229008)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neuromyelitis optica spectrum disorder, anti-MOG antibodies, aquaporin-4 antibodies, seronegative NMOSD, clinical features, optic neuritis, spinal cord lesions, disease phenotypes, functional recovery, relapse rate
- MeSH terms
- Adolescent, Adult, Aged, Autoantibodies, Child, Preschool, Female, Humans, Male, Middle Aged, Neuromyelitis Optica, Phenotype, Sex Factors, Aquaporin 4, Young Adult, Myelin-Oligodendrocyte Glycoprotein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
